Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Assessing the protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in humans.

Christensen SR, Toulmin SA, Griesman T, Lamerato LE, Petrie JG, Martin ET, Monto AS, Hensley SE.

J Virol. 2019 Jan 30. pii: JVI.02134-18. doi: 10.1128/JVI.02134-18. [Epub ahead of print]

2.

Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens.

Zost SJ, Wu NC, Hensley SE, Wilson IA.

J Infect Dis. 2018 Dec 9. doi: 10.1093/infdis/jiy696. [Epub ahead of print] No abstract available.

PMID:
30535315
3.

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.

Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karikó K, Barbosa CJ, Madden TD, Hope MJ, Krammer F, Hensley SE, Weissman D.

Nat Commun. 2018 Aug 22;9(1):3361. doi: 10.1038/s41467-018-05482-0.

4.

Sera from Individuals with Narrowly Focused Influenza Virus Antibodies Rapidly Select Viral Escape Mutations In Ovo.

Davis AKF, McCormick K, Gumina ME, Petrie JG, Martin ET, Xue KS, Bloom JD, Monto AS, Bushman FD, Hensley SE.

J Virol. 2018 Sep 12;92(19). pii: e00859-18. doi: 10.1128/JVI.00859-18. Print 2018 Oct 1.

PMID:
30045982
5.

Identification of human vaccinees that possess antibodies targeting the egg-adapted hemagglutinin receptor binding site of an H1N1 influenza vaccine strain.

Garretson TA, Petrie JG, Martin ET, Monto AS, Hensley SE.

Vaccine. 2018 Jun 27;36(28):4095-4101. doi: 10.1016/j.vaccine.2018.05.086. Epub 2018 May 31.

PMID:
29861178
6.

The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.

Jain S, George PJ, Deng W, Koussa J, Parkhouse K, Hensley SE, Jiang J, Lu J, Liu Z, Wei J, Zhan B, Bottazzi ME, Shen H, Lustigman S.

Vaccine. 2018 Jun 14;36(25):3650-3665. doi: 10.1016/j.vaccine.2018.05.029.

PMID:
29764680
7.

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D.

J Exp Med. 2018 Jun 4;215(6):1571-1588. doi: 10.1084/jem.20171450. Epub 2018 May 8.

8.

Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013.

Cobey S, Gouma S, Parkhouse K, Chambers BS, Ertl HC, Schmader KE, Halpin RA, Lin X, Stockwell TB, Das SR, Landon E, Tesic V, Youngster I, Pinsky BA, Wentworth DE, Hensley SE, Grad YH.

Clin Infect Dis. 2018 Jul 18;67(3):327-333. doi: 10.1093/cid/ciy097.

9.

Genomic Circuitry Underlying Immunological Response to Pediatric Acute Respiratory Infection.

Henrickson SE, Manne S, Dolfi DV, Mansfield KD, Parkhouse K, Mistry RD, Alpern ER, Hensley SE, Sullivan KE, Coffin SE, Wherry EJ.

Cell Rep. 2018 Jan 9;22(2):411-426. doi: 10.1016/j.celrep.2017.12.043.

10.

Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.

Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, Treanor JJ, Sant AJ, Cobey S, Hensley SE.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583. doi: 10.1073/pnas.1712377114. Epub 2017 Nov 6.

11.

A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine.

Wu NC, Zost SJ, Thompson AJ, Oyen D, Nycholat CM, McBride R, Paulson JC, Hensley SE, Wilson IA.

PLoS Pathog. 2017 Oct 23;13(10):e1006682. doi: 10.1371/journal.ppat.1006682. eCollection 2017 Oct.

12.

Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells.

Herati RS, Muselman A, Vella L, Bengsch B, Parkhouse K, Del Alcazar D, Kotzin J, Doyle SA, Tebas P, Hensley SE, Su LF, Schmader KE, Wherry EJ.

Sci Immunol. 2017 Feb;2(8). pii: eaag2152. doi: 10.1126/sciimmunol.aag2152. Epub 2017 Feb 17.

13.

Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies.

Willis E, Hensley SE.

Virology. 2017 Aug;508:1-6. doi: 10.1016/j.virol.2017.04.031. Epub 2017 May 2.

14.

Complete mapping of viral escape from neutralizing antibodies.

Doud MB, Hensley SE, Bloom JD.

PLoS Pathog. 2017 Mar 13;13(3):e1006271. doi: 10.1371/journal.ppat.1006271. eCollection 2017 Mar.

15.

Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination.

Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, Dowd KA, Sutherland LL, Scearce RM, Parks R, Wagner W, Granados A, Greenhouse J, Walker M, Willis E, Yu JS, McGee CE, Sempowski GD, Mui BL, Tam YK, Huang YJ, Vanlandingham D, Holmes VM, Balachandran H, Sahu S, Lifton M, Higgs S, Hensley SE, Madden TD, Hope MJ, Karikó K, Santra S, Graham BS, Lewis MG, Pierson TC, Haynes BF, Weissman D.

Nature. 2017 Mar 9;543(7644):248-251. doi: 10.1038/nature21428. Epub 2017 Feb 2.

16.

Immune history and influenza virus susceptibility.

Cobey S, Hensley SE.

Curr Opin Virol. 2017 Feb;22:105-111. doi: 10.1016/j.coviro.2016.12.004. Epub 2017 Jan 12. Review.

17.

Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains.

Petrie JG, Parkhouse K, Ohmit SE, Malosh RE, Monto AS, Hensley SE.

J Infect Dis. 2016 Dec 15;214(12):1947-1951. Epub 2016 Oct 7.

18.

Canine H3N8 influenza vaccines partially protect mice against the canine H3N2 strain currently circulating in the United States.

Willis E, Parkhouse K, Krammer F, Hensley SE.

Vaccine. 2016 Nov 4;34(46):5483-5487. doi: 10.1016/j.vaccine.2016.09.017. Epub 2016 Sep 24.

19.

Characterization of Femoral Component Initial Stability and Cortical Strain in a Reduced Stem-Length Design.

Small SR, Hensley SE, Cook PL, Stevens RA, Rogge RD, Meding JB, Berend ME.

J Arthroplasty. 2017 Feb;32(2):601-609. doi: 10.1016/j.arth.2016.07.033. Epub 2016 Aug 10.

PMID:
27597431
20.

Antibodies with 'Original Antigenic Sin' Properties Are Valuable Components of Secondary Immune Responses to Influenza Viruses.

Linderman SL, Hensley SE.

PLoS Pathog. 2016 Aug 18;12(8):e1005806. doi: 10.1371/journal.ppat.1005806. eCollection 2016 Aug.

21.

Cutting Edge: IL-4, IL-21, and IFN-γ Interact To Govern T-bet and CD11c Expression in TLR-Activated B Cells.

Naradikian MS, Myles A, Beiting DP, Roberts KJ, Dawson L, Herati RS, Bengsch B, Linderman SL, Stelekati E, Spolski R, Wherry EJ, Hunter C, Hensley SE, Leonard WJ, Cancro MP.

J Immunol. 2016 Aug 15;197(4):1023-8. doi: 10.4049/jimmunol.1600522. Epub 2016 Jul 18.

22.

Propagation and Characterization of Influenza Virus Stocks That Lack High Levels of Defective Viral Genomes and Hemagglutinin Mutations.

Xue J, Chambers BS, Hensley SE, López CB.

Front Microbiol. 2016 Mar 23;7:326. doi: 10.3389/fmicb.2016.00326. eCollection 2016.

23.

Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza Season.

Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE.

Cell Rep. 2015 Jul 7;12(1):1-6. doi: 10.1016/j.celrep.2015.06.005. Epub 2015 Jun 25.

24.

Multiplexed detection of viral infections using rapid in situ RNA analysis on a chip.

Shaffer SM, Joshi RP, Chambers BS, Sterken D, Biaesch AG, Gabrieli DJ, Li Y, Feemster KA, Hensley SE, Issadore D, Raj A.

Lab Chip. 2015 Aug 7;15(15):3170-82. doi: 10.1039/c5lc00459d.

25.

Novel synthetic plasmid and Doggybone DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice.

Scott VL, Patel A, Villarreal DO, Hensley SE, Ragwan E, Yan J, Sardesai NY, Rothwell PJ, Extance JP, Caproni LJ, Weiner DB.

Hum Vaccin Immunother. 2015;11(8):1972-82. doi: 10.1080/21645515.2015.1022008.

26.

RNASEK is required for internalization of diverse acid-dependent viruses.

Hackett BA, Yasunaga A, Panda D, Tartell MA, Hopkins KC, Hensley SE, Cherry S.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):7797-802. doi: 10.1073/pnas.1424098112. Epub 2015 Jun 8.

27.

HSV-1 remodels host telomeres to facilitate viral replication.

Deng Z, Kim ET, Vladimirova O, Dheekollu J, Wang Z, Newhart A, Liu D, Myers JL, Hensley SE, Moffat J, Janicki SM, Fraser NW, Knipe DM, Weitzman MD, Lieberman PM.

Cell Rep. 2014 Dec 24;9(6):2263-78. doi: 10.1016/j.celrep.2014.11.019. Epub 2014 Dec 11.

28.

Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season.

Linderman SL, Chambers BS, Zost SJ, Parkhouse K, Li Y, Herrmann C, Ellebedy AH, Carter DM, Andrews SF, Zheng NY, Huang M, Huang Y, Strauss D, Shaz BH, Hodinka RL, Reyes-Terán G, Ross TM, Wilson PC, Ahmed R, Bloom JD, Hensley SE.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15798-803. doi: 10.1073/pnas.1409171111. Epub 2014 Oct 20.

29.

Editorial overview: viral evolution: exploring the frontiers of virus evolution in the lab, the field and the clinic.

Brockhurst MA, Hensley SE.

Curr Opin Virol. 2014 Oct;8:ix-x. doi: 10.1016/j.coviro.2014.09.002. Epub 2014 Sep 13. No abstract available.

PMID:
25224393
30.

Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories.

Hensley SE.

Curr Opin Virol. 2014 Oct;8:85-9. doi: 10.1016/j.coviro.2014.07.007. Epub 2014 Aug 11. Review.

31.

Coinfection with Streptococcus pneumoniae modulates the B cell response to influenza virus.

Wolf AI, Strauman MC, Mozdzanowska K, Whittle JR, Williams KL, Sharpe AH, Weiser JN, Caton AJ, Hensley SE, Erikson J.

J Virol. 2014 Oct;88(20):11995-2005. doi: 10.1128/JVI.01833-14. Epub 2014 Aug 6.

32.

Pneumolysin expression by streptococcus pneumoniae protects colonized mice from influenza virus-induced disease.

Wolf AI, Strauman MC, Mozdzanowska K, Williams KL, Osborne LC, Shen H, Liu Q, Garlick D, Artis D, Hensley SE, Caton AJ, Weiser JN, Erikson J.

Virology. 2014 Aug;462-463:254-65. doi: 10.1016/j.virol.2014.06.019. Epub 2014 Jul 5.

33.

Recent H3N2 influenza virus clinical isolates rapidly acquire hemagglutinin or neuraminidase mutations when propagated for antigenic analyses.

Chambers BS, Li Y, Hodinka RL, Hensley SE.

J Virol. 2014 Sep;88(18):10986-9. doi: 10.1128/JVI.01077-14. Epub 2014 Jul 2.

34.

Antigen sparing and enhanced protection using a novel rOv-ASP-1 adjuvant in aqueous formulation with influenza vaccines.

Jiang J, Fisher EM, Hensley SE, Lustigman S, Murasko DM, Shen H.

Vaccine. 2014 May 13;32(23):2696-702. doi: 10.1016/j.vaccine.2014.03.046. Epub 2014 Mar 26.

35.

Compensatory hemagglutinin mutations alter antigenic properties of influenza viruses.

Myers JL, Wetzel KS, Linderman SL, Li Y, Sullivan CB, Hensley SE.

J Virol. 2013 Oct;87(20):11168-72. doi: 10.1128/JVI.01414-13. Epub 2013 Aug 7.

36.

Immune history shapes specificity of pandemic H1N1 influenza antibody responses.

Li Y, Myers JL, Bostick DL, Sullivan CB, Madara J, Linderman SL, Liu Q, Carter DM, Wrammert J, Esposito S, Principi N, Plotkin JB, Ross TM, Ahmed R, Wilson PC, Hensley SE.

J Exp Med. 2013 Jul 29;210(8):1493-500. doi: 10.1084/jem.20130212. Epub 2013 Jul 15.

37.

Single hemagglutinin mutations that alter both antigenicity and receptor binding avidity influence influenza virus antigenic clustering.

Li Y, Bostick DL, Sullivan CB, Myers JL, Griesemer SB, Stgeorge K, Plotkin JB, Hensley SE.

J Virol. 2013 Sep;87(17):9904-10. doi: 10.1128/JVI.01023-13. Epub 2013 Jul 3.

38.

Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selection.

Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW.

Cell Host Microbe. 2013 Mar 13;13(3):314-23. doi: 10.1016/j.chom.2013.02.008.

39.

Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy.

Das SR, Hensley SE, David A, Schmidt L, Gibbs JS, Puigbò P, Ince WL, Bennink JR, Yewdell JW.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):E1417-22. doi: 10.1073/pnas.1108754108. Epub 2011 Nov 21.

40.

Oseltamivir-resistant influenza viruses get by with a little help from permissive mutations.

Myers JL, Hensley SE.

Expert Rev Anti Infect Ther. 2011 Apr;9(4):385-8. doi: 10.1586/eri.11.2.

41.

Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance.

Hensley SE, Das SR, Gibbs JS, Bailey AL, Schmidt LM, Bennink JR, Yewdell JW.

PLoS One. 2011 Feb 22;6(2):e15190. doi: 10.1371/journal.pone.0015190.

42.

Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain.

Das SR, Puigbò P, Hensley SE, Hurt DE, Bennink JR, Yewdell JW.

PLoS Pathog. 2010 Nov 24;6(11):e1001211. doi: 10.1371/journal.ppat.1001211.

43.

Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses.

Hensley SE, Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W, Bennink JR, Yewdell JW.

J Immunol. 2010 Apr 15;184(8):4115-22. doi: 10.4049/jimmunol.0903003. Epub 2010 Mar 12.

44.

Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift.

Hensley SE, Das SR, Bailey AL, Schmidt LM, Hickman HD, Jayaraman A, Viswanathan K, Raman R, Sasisekharan R, Bennink JR, Yewdell JW.

Science. 2009 Oct 30;326(5953):734-6. doi: 10.1126/science.1178258.

45.

Que sera, sera: evolution of the swine H1N1 influenza A virus.

Hensley SE, Yewdell JW.

Expert Rev Anti Infect Ther. 2009 Sep;7(7):763-8. doi: 10.1586/eri.09.62. No abstract available.

46.

Murine norovirus infection has no significant effect on adaptive immunity to vaccinia virus or influenza A virus.

Hensley SE, Pinto AK, Hickman HD, Kastenmayer RJ, Bennink JR, Virgin HW, Yewdell JW.

J Virol. 2009 Jul;83(14):7357-60. doi: 10.1128/JVI.00623-09. Epub 2009 Apr 29.

47.

Effect of preexisting immunity on an adenovirus vaccine vector: in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo.

Pichla-Gollon SL, Lin SW, Hensley SE, Lasaro MO, Herkenhoff-Haut L, Drinker M, Tatsis N, Gao GP, Wilson JM, Ertl HC, Bergelson JM.

J Virol. 2009 Jun;83(11):5567-73. doi: 10.1128/JVI.00405-09. Epub 2009 Mar 11.

48.

Plasmacytoid dendritic cells are dispensable during primary influenza virus infection.

Wolf AI, Buehler D, Hensley SE, Cavanagh LL, Wherry EJ, Kastner P, Chan S, Weninger W.

J Immunol. 2009 Jan 15;182(2):871-9.

49.

Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses.

Lasaro MO, Tatsis N, Hensley SE, Whitbeck JC, Lin SW, Rux JJ, Wherry EJ, Cohen GH, Eisenberg RJ, Ertl HC.

Nat Med. 2008 Feb;14(2):205-12. doi: 10.1038/nm1704. Epub 2008 Jan 13.

50.

Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes.

Hickman HD, Takeda K, Skon CN, Murray FR, Hensley SE, Loomis J, Barber GN, Bennink JR, Yewdell JW.

Nat Immunol. 2008 Feb;9(2):155-65. doi: 10.1038/ni1557. Epub 2008 Jan 13.

PMID:
18193049

Supplemental Content

Loading ...
Support Center